Mary Ann and Charles LaBahn Pancreatic Cancer Program

Our pancreatic cancer team includes a diverse group of physicians and scientists with an international reputation for clinical care and research. A continuous dedication to research is what sets us apart. It creates opportunities for patients to participate in clinical trials that often lead to innovative therapies. Schedule an Appointment

A Gift that Continues Our Tradition of Leading the Way

Endowed through a generous gift from Mary Ann and Charles LaBahn, the Pancreatic Cancer Program is comprised of a multidisciplinary team of physicians, scientists, and dedicated staff who share the LaBahns' passion and urgency for making significant progress in the battle against pancreatic cancer.

The Mary Ann and Charles LaBahn Pancreatic Cancer Program serves as a hub for innovation where physicians and scientists are focused on providing hope for a cure to patients and families with pancreatic cancer. The LaBahns’ generosity allows for high-risk, high-reward research leading toward more effective therapies and treatment options for patients with this devastating disease. This philanthropic investment will hasten the pace at which our team can translate laboratory discoveries into treatments for patients.

Our "Surgery Last" Approach

Because of the complicated nature of pancreatic cancer, patients require several different kinds of treatment. We believe that multidisciplinary care is the best option for successful treatment. This is important for patients with localized, operable cancer, since multimodality treatments have been shown to deliver the best outcomes. Our research and program helped to spearhead the “surgery last” approach, which advocates for quick and early delivery of chemotherapy and radiation. Not only does this promote the best chance of controlling the cancer, it sets the stage for successful surgery.

learn more

Clinical Trials Provide Opportunities for Current and Future Patients

Our program is committed to translating research into cutting-edge treatments for our patients. We prioritize the rapid translation of basic science discoveries into improved treatments that impact our community.

learn more